Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002758418 | SCV003579659 | uncertain significance | Inborn genetic diseases | 2021-10-12 | criteria provided, single submitter | clinical testing | The c.4559C>T (p.S1520L) alteration is located in exon 15 (coding exon 14) of the GLI3 gene. This alteration results from a C to T substitution at nucleotide position 4559, causing the serine (S) at amino acid position 1520 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004529231 | SCV004105362 | uncertain significance | GLI3-related disorder | 2023-04-13 | criteria provided, single submitter | clinical testing | The GLI3 c.4559C>T variant is predicted to result in the amino acid substitution p.Ser1520Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.064% of alleles in individuals of East Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/7-42004112-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Labcorp Genetics |
RCV005227834 | SCV005864837 | likely benign | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome | 2024-08-02 | criteria provided, single submitter | clinical testing |